Cancer Home > Omacetaxine Mepesuccinate Information

As a type of chemotherapy treatment, omacetaxine mepesuccinate (SynriboTM) is approved to treat a type of blood and bone marrow cancer called chronic myeloid leukemia (CML). It is used when at least two other forms of treatment have been tried without success. Omacetaxine is approved for use only in adults only.
It comes as an injection that is given just beneath the skin (subcutaneously). The drug is given by a healthcare provider twice daily for 7 to 14 days, followed by a break in treatment. Side effects are common and may include diarrhea, anemia, and fatigue.
If your healthcare provider recommends chemotherapy treatment with omacetaxine mepesuccinate, he or she will need information on your medical history and any other medications, vitamins, or supplements you are using. You should also talk to your healthcare provider if you are pregnant or have any allergies.
(To learn more about this chemotherapy treatment, click Omacetaxine. This full-length article provides more information, including details on how the drug works, what to expect during treatment, and other important warnings and precautions.)
Written by/reviewed by:
Last reviewed by: Arthur Schoenstadt, MD
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation




Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.